A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer - Phase 3 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC

Incyte Corporation0 个研究点目标入组 1,062 人开始时间: 2017年11月7日最近更新: 2018年7月23日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Incyte Corporation
入组人数: 1,062

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Have a histologically or cytologically confirmed diagnosis of stage IV (AJCC version 8 or current version as applicable) NSCLC.
•2. Have confirmation that EGFR, ALK, or ROS1 directed therapy is not indicated as primary therapy (documentation of absence of tumor activating EGFR mutations AND absence of ALK and ROS1 gene rearrangements OR presence of a KRAS mutation).
•a. If participant’s tumor is known to have a predominantly squamous histology, molecular testing for EGFR mutation and ALK and ROS1 translocations will not be required, as this is not part of current diagnostic guidelines.
•3. Have measurable disease based on RECIST 1.1 as determined by the local site. a. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
•4. Be =18 years of age on the day of signing informed consent.
•5. Have a life expectancy of at least 3 months.
•6. Have an ECOG performance status of 0 or 1 within 7 days prior to the first dose of study treatment but before randomization.
•7. A male participant must agree to use contraception as detailed in Appendix 2 of this protocol during the treatment period and for at least 120 days after the last dose of pembrolizumab and epacadostat/matching placebo and up to 180 days after last dose of chemotherapeutic agents.
•8. A female participant is eligible to participate if she is not pregnant (see Appendix 2 of the protocol), not breastfeeding, and at least one of the following conditions applies:
•a. Not a woman of childbearing potential (WOCBP) as defined in Appendix 2
•b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during the treatment period and for at least 120 days after the last dose of pembrolizumab and epacadostat/matching placebo and up to 180 days after last dose of chemotherapeutic agents.
•9. The participant (or legally acceptable representative if applicable) provides written informed consent for the study.
•10. Have adequate organ function as indicated by the laboratory values as defined in the protocol Specimens must be collected and reviewed within 10 days prior to the start of study treatment.
•11. Have provided an evaluable archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion (that was not previously irradiated) for central PD-L1 testing. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 531
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 531

排除标准

•1. Has known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, clinically stable, and have not required steroids for at least 14 days before first dose of study treatment
•2. Has a history of (non-infectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease
•3. Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions is eligible
•4. Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy
•5. Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
•6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
•7. Has had an allogeneic tissue/solid organ transplant
•8. Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority
•9. Has known history of or is positive for active Hepatitis B (HBsAg reactive) or has active Hepatitis C (HCV RNA)
•10. Has a history of a gastrointestinal condition or procedure that in the opinion of the Investigator may affect oral drug absorption
•11. Has a history or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful. Screening QTc interval >480 msec is excluded (corrected by Fridericia or Bazett formula)
•12. Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure. Medically controlled arrhythmia stable on medication is permitted
•13. Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
•14. Has an active infection requiring systemic therapy
•15. Has known psychiatric or substance abuse disorders that would interfere with the participant’s cooperation for the requirements of the study
•16. Previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity to any component of epacadostat, pembrolizumab, or as applicable, carboplatin, cisplatin, paclitaxel, or pemetrexed
•17. WOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
•18. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and epacadostat/matching placebo and up to 180 days after last dose of chemotherapeutic agents
•19. Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC
•20. Has received prior treatment with pembrolizumab or any other anti-PD-1, anti-PD-L1, anti-PD-L2 agent, with epacadostat or any anti

研究者

发起方

Incyte Corporation

相似试验

进行中（未招募）

1 期

Phase 3 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLCFirst-line treatment of metastatic NSCLCMedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2017-001810-27-FRIncyte Corporation233

进行中（未招募）

1 期

EUCTR2017-001810-27-ESIncyte Corporation233

进行中（未招募）

1 期

A study of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in patients with lung canceron-Small Cell Lung Cancer

EUCTR2017-001311-36-PLRegeneron Pharmaceuticals, Inc.500

进行中（未招募）

1 期

A study of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in patients with lung canceron-Small Cell Lung Cancer

EUCTR2017-001311-36-RORegeneron Pharmaceuticals, Inc.500

进行中（未招募）

1 期

A study of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in patients with lung canceron-Small Cell Lung Cancer

EUCTR2017-001311-36-IERegeneron Pharmaceuticals, Inc.500